Cancer Chemotherapy and Pharmacology

, Volume 74, Issue 5, pp 1047–1055 | Cite as

Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma

  • Ami V. Desai
  • Elizabeth Fox
  • L. Mary Smith
  • Allison Pecha Lim
  • John M. Maris
  • Frank M. Balis
Original Article

Abstract

Purpose

Ch14.18 improves survival in children with high-risk neuroblastoma but is associated with substantial toxicity. Ch14.18 pharmacokinetics were previously reported to be highly variable and characterized by a higher clearance in children than in adults, and a large volume of distribution. Identifying factors responsible for its variability could lead to alternative dosing strategies that reduce toxicity.

Methods

Plasma sampling was performed prior to, during, and for 25 days after four daily 10-h infusions of 25 mg/m2 of ch14.18 administered with sargramostim. Ch14.18 concentrations were quantified with an electrochemiluminescence immunoassay, and pharmacokinetic parameters were derived using non-compartmental methods and from fitting a two-compartment model. Human anti-chimeric antibody (HACA) was measured before each course.

Results

Fourteen subjects (median age, 4.3 years) were enrolled; seven had sampling on two courses to assess intra-subject variability. Mean peak ch14.18 plasma concentration was 11 µg/mL, and disappearance was biexponential with half-life of 7 days. Mean trough (day 28) concentration was 0.2 µg/mL. Mean AUC0–∞ was 1,380 µg h/mL and was less variable than previously reported (CV 29 %). Intra-patient variability was also minimal, but one subject who developed HACA had a 41 % decrease in AUC0–tlast from courses 1 to 3. Clearance (2 L/day m2) was fourfold higher in children than in adults and appeared to be age dependent. Steady state volume of distribution was 0.4 L/kg. Two-compartment model parameters were used to simulate alternative dosing schedules.

Conclusions

Ch14.18 disposition in children is less variable than previously reported. Clearance is age dependent and more rapid in younger children.

Keywords

Pharmacokinetics Ch14.18 Dinutuximab Neuroblastoma Child 

Supplementary material

280_2014_2575_MOESM1_ESM.docx (74 kb)
Supplementary material 1 (DOCX 73 kb)
280_2014_2575_MOESM2_ESM.docx (69 kb)
Supplementary material 2 (DOCX 69 kb)
280_2014_2575_MOESM3_ESM.docx (165 kb)
Supplemental Fig. 1 Observational pain score sheet given to parents of subjects to complete prior to, 2 h after the start of each infusion, and at the end of each infusion of ch14.18. A final pain score sheet was completed the morning after the fourth ch14.18 infusion(DOCX 164 kb)

References

  1. 1.
    Hettmer S, Ladisch S, Kaucic K (2005) Low complex ganglioside expression characterizes human neuroblastoma cell lines. Cancer Lett 225(1):141–149. doi:10.1016/j.canlet.2004.11.036 PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Lo Piccolo MS, Cheung NK, Cheung IY (2001) GD2 synthase: a new molecular marker for detecting neuroblastoma. Cancer 92(4):924–931PubMedCrossRefGoogle Scholar
  3. 3.
    Sariola H, Terava H, Rapola J, Saarinen UM (1991) Cell-surface ganglioside GD2 in the immunohistochemical detection and differential diagnosis of neuroblastoma. Am J Clin Pathol 96(2):248–252PubMedGoogle Scholar
  4. 4.
    Wu ZL, Schwartz E, Seeger R, Ladisch S (1986) Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res 46(1):440–443PubMedGoogle Scholar
  5. 5.
    DA Cheresh HJ, Schulz G, Reisfeld RA (1984) Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci USA 81(18):5767–5771PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Cheung NKLH, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF, Berger NA (1987) Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5(9):1430–1440PubMedGoogle Scholar
  7. 7.
    Roth MLM, Tarim J, Piperdi S, Sowers R, Geller D, Gill J, Gorlick R (2014) Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer 120(4):548–554PubMedCrossRefGoogle Scholar
  8. 8.
    Svennerholm L, Bostrom K, Fredman P, Jungbjer B, Lekman A, Mansson JE, Rynmark BM (1994) Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim Biophys Acta 1214(2):115–123PubMedCrossRefGoogle Scholar
  9. 9.
    Zeng Y, Fest S, Kunert R, Katinger H, Pistoia V, Michon J, Lewis G, Ladenstein R, Lode HN (2005) Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol 42(11):1311–1319. doi:10.1016/j.molimm.2004.12.018 PubMedCrossRefGoogle Scholar
  10. 10.
    Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. New Engl J Med 363(14):1324–1334. doi:10.1056/NEJMoa0911123 PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Saleh MN, Khazaeli MB, Wheeler RH, Allen L, Tilden AB, Grizzle W, Reisfeld RA, Yu AL, Gillies SD, LoBuglio AF (1992) Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas 3(1):19–24PubMedGoogle Scholar
  12. 12.
    Gilman AL, Ozkaynak MF, Matthay KK, Krailo M, Yu AL, Gan J, Sternberg A, Hank JA, Seeger R, Reaman GH, Sondel PM (2009) Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children’s Oncology Group. J Clin Oncol 27(1):85–91. doi:10.1200/JCO.2006.10.3564 PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Handgretinger R, Anderson K, Lang P, Dopfer R, Klingebiel T, Schrappe M, Reuland P, Gillies SD, Reisfeld RA, Neithammer D (1995) A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 31A(2):261–267PubMedCrossRefGoogle Scholar
  14. 14.
    Ozkaynak MF, Sondel PM, Krailo MD, Gan J, Javorsky B, Reisfeld RA, Matthay KK, Reaman GH, Seeger RC (2000) Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children’s Cancer Group Study. Journal of clinical oncology: official journal of the American Society of. Clin Oncol 18(24):4077–4085Google Scholar
  15. 15.
    Yu AL, Uttenreuther-Fischer MM, Huang CS, Tsui CC, Gillies SD, Reisfeld RA, Kung FH (1998) Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 16(6):2169–2180PubMedGoogle Scholar
  16. 16.
    Murray JL, Kleinerman ES, Jia SF, Rosenblum MG, Eton O, Buzaid A, Legha S, Ross MI, Thompson L, Mujoo K, Rieger PT, Saleh M, Khazaeli MB, Vadhan-Raj S (1996) Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J Immunother Emphas Tumor Immunol 19(3):206–217CrossRefGoogle Scholar
  17. 17.
    Albertini MR, Hank JA, Schiller JH, Khorsand M, Borchert AA, Gan J, Bechhofer R, Storer B, Reisfeld RA, Sondel PM (1997) Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin Cancer Res 3(8):1277–1288PubMedGoogle Scholar
  18. 18.
    Uttenreuther-Fischer MM, Huang CS, Yu AL (1995) Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients. Cancer Immunol Immunother 41(6):331–338PubMedCrossRefGoogle Scholar
  19. 19.
    Dirks NL, Meibohm B (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49(10):633–659. doi:10.2165/11535960-000000000-00000 PubMedCrossRefGoogle Scholar
  20. 20.
    Keizer RJ, Huitema AD, Schellens JH, Beijnen JH (2010) Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49(8):493–507. doi:10.2165/11531280-000000000-00000 PubMedCrossRefGoogle Scholar
  21. 21.
    Merkel SIV-LT, Shayevitz JR, Malviya S (1997) The FLACC: a behavioral scale for scoring postoperative pain in young children. Pract Appl Res 23(3):293–297Google Scholar
  22. 22.
    Baxter LTZH, Mackensen DG, Jain RK (1994) Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 54(6):1517–1528PubMedGoogle Scholar
  23. 23.
    Wang WWE, Balthasar JP (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84(5):548–558PubMedCrossRefGoogle Scholar
  24. 24.
    Schellekens H (2002) Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24(11):1720–1740PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Ami V. Desai
    • 1
  • Elizabeth Fox
    • 1
  • L. Mary Smith
    • 2
  • Allison Pecha Lim
    • 2
  • John M. Maris
    • 1
  • Frank M. Balis
    • 1
  1. 1.Division of OncologyThe Children’s Hospital of PhiladelphiaPhiladelphiaUSA
  2. 2.United Therapeutics CorporationResearch Triangle ParkUSA

Personalised recommendations